CATEGORY

Cell Therapies

Cell therapies is a fast growing biologic drug category where cellular material is used in the treatment process

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Cell Therapies.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Cell Therapies Suppliers


    Cell Therapies Supplier

    Find the right-fit cell therapies supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Cell Therapies market report transcript


    Cell Therapies Supplier Market Overview

    • The supplier market is fragmented and developing. Academic institutions are the major supply base for this market due to the access to skilled labor and government funded research programs.
    • 70 percent of the clinical trials were sponsored by the academic institutions (with public funds) and 30 percent by CROs for cell therapy in 2015
    • The US and Canada are the leading markets for cell therapy and most of the suppliers, CROs, as well as academia are populated in this region. Europe is the second leading market with several universities focusing on cell therapy
    • Academia will continue to be the key supply base due to the complexity of trials, safety concerns and the relatively lower business risk inclination of CROs for cell therapy trials
    • Preliminary results in Phase I and II of such trials, which have minor benefits in extensive Phase III research (due to population heterogeneity), and limited evidence of efficacy of these trials makes it a technically challenging service line

    cell-therapies-market-size

    Technology Overview

    Supply Chain Concerns 

    • For individual supply chains, the number of suppliers available are few
    • To mitigate risk, companies prefer manufacturing these materials in-house at this stage

    Open Innovation in Stem Cells 

    The industry is practicing open innovation in this category 

    • Stem cells are available for development, to researchers, by Luna, California Institute for Regenerative Medicine and the European Biobank
    • Such banks are estimated to save up to six months and $50,000–100,000 per patient
    • Cellsartis AB has been asked to share its cell lines
    • Lonza has publicly released documents regarding its GMP approved stem cell manufacturing technology encouraging further innovation

    Cell Therapies-Market Trends

    Drivers

    • T-cell research conducted by non-pharmaceutical organizations is more advanced than pharmaceutical organizations
    • As T-ell therapies are receiving priority reviews, outsourcing research activities to organizations focusing on different types of T-cell therapies can provide market advantages
    • Open innovation in the stem cells industry is encouraging research in development of therapies and manufacturing practices
    • This is a result of allowing public use of private cell banks and advanced manufacturing practices
    • As standardized manufacturing techniques are developed, the market is expected to expand

    Constraints

    • Stem cells can differentiate into more than 200 lines
    • As manufacturing practices for stable cell lines have not been established, outsourcing manufacturing capabilities is a concern
    • For autologous cell therapies, which are the most common therapies, involves cells from individual patients; the concept of commercial batch manufacturing is difficult to establish
    • This will also involve location constraints
    • Existing centrifugal and filtration techniques are not feasible to harvest and recover live cells
    • The supply chains established by non-pharmaceutical organizations have high levels of risk
    • As a lot of small suppliers own the IP for various technologies contributing to the supply chain, organizations are forced to rely heavily on these suppliers for their internal processes leaving their supply chains vulnerable to risk

    Cell Therapy Market Overview

    • Due to the lack of many upstream suppliers, the supply chain risk is much higher for T-cells. 
    • The spend for stem cells is higher owing to the higher maturity of the stem cell therapy market.
    • The stem cell therapy market is more mature and attracts a higher investment value from pharmaceutical companies and research institutes.
    • T-cells is expected to move to a similar position in the next few years.
    • In the T-cells category, the number of suppliers and customers are low due to low maturity and research progress.
    • For T-cells, it is difficult to implement a supplier relationship due to the intricate supply chain balance in the previous tiers.
    • The stem cell therapy market has reached an advanced stage with increased commercialization prospects.
    • To establish low risk, a stable supply chain, long term strategic relationships can be used.
    • The intensity of rivalry is medium among pharmaceutical companies as this is a high risk segment and few companies are investing directly (or) indirectly in stem cell technologies.
    • The technology has still not achieved maturity.
    • However, multiple CROs are still conducting research in the stem cell therapy market. 
    • As the technology is maturing, more pharmaceutical companies are investing in this technology.
    • As the technology matures and regulations are standardized, it becomes easier for suppliers to enter the industry.
    • Substitutes for regenerative medicine is low.
    • Major biopharmaceutical companies are expressing increasing interest in advanced therapies, generally through collaboration and co-development type agreements.
    • Pharmaceutical companies are key stakeholders in both directly developing, acquiring, and sponsoring and supporting smaller biotech companies.

    Why You Should Buy This Report

    • Information about cell therapy market size, technology and supplier overview, cell therapy market analysis, market trends, drivers and constraints, etc.
    • Porter’s five force analysis of the stem cell therapy market and T-cell therapy market.
    • Supplier profiling, analysis and best industry practices.